FOI_8811

Internal Reference Number: FOI_8811

Date Request Received: 31/07/2025 00:00:00

Date Request Replied To: 19/08/2025 00:00:00

This response was sent via: By Email

Request Summary: Oncology MF

Request Category: Companies


Question Number 1: How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months) • Myelofibrosis (ICD-10 code: D47.4) • Polycythaemia Vera (ICD-10 code: D45)

Answer To Question 1: Please see our response to all questions in the attached file. To accompany this answer to question 1 please also see the documents listed below: 13167 - FOI_8811 - Oncology MF - FOR ISSUE.xlsx

Question Number 2: How many patients were initiated on the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months) • Fedratinib • Momelotinib

Answer To Question 2: Please see attached

Question Number 3: How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with? • Hydroxycarbamide • Interferon therapy

Answer To Question 3: Please see attached
Please see Attachments:


To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.